CN113797380A - 一种释氧敷料及其制备方法和应用 - Google Patents
一种释氧敷料及其制备方法和应用 Download PDFInfo
- Publication number
- CN113797380A CN113797380A CN202111008145.2A CN202111008145A CN113797380A CN 113797380 A CN113797380 A CN 113797380A CN 202111008145 A CN202111008145 A CN 202111008145A CN 113797380 A CN113797380 A CN 113797380A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- hydrogel layer
- layer
- freeze
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001301 oxygen Substances 0.000 title claims abstract description 125
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 125
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 124
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000017 hydrogel Substances 0.000 claims abstract description 96
- 239000000499 gel Substances 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000002978 peroxides Chemical class 0.000 claims abstract description 30
- 238000000016 photochemical curing Methods 0.000 claims abstract description 27
- 229940094522 laponite Drugs 0.000 claims abstract description 24
- 239000000178 monomer Substances 0.000 claims abstract description 24
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 21
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 21
- 238000004108 freeze drying Methods 0.000 claims abstract description 17
- 239000003999 initiator Substances 0.000 claims abstract description 17
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 25
- 206010052428 Wound Diseases 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 108700004892 gelatin methacryloyl Proteins 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 claims description 6
- 230000035699 permeability Effects 0.000 claims description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- 239000004343 Calcium peroxide Substances 0.000 claims description 5
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 claims description 5
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical group [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 5
- 235000019402 calcium peroxide Nutrition 0.000 claims description 5
- 125000004386 diacrylate group Chemical group 0.000 claims description 5
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims description 5
- 229960004995 magnesium peroxide Drugs 0.000 claims description 5
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 5
- 229940045872 sodium percarbonate Drugs 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229950011087 perflunafene Drugs 0.000 claims description 3
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000002045 lasting effect Effects 0.000 abstract 1
- 229910052642 spodumene Inorganic materials 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 39
- 229920002451 polyvinyl alcohol Polymers 0.000 description 39
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000002640 oxygen therapy Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229920006264 polyurethane film Polymers 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 208000003790 Foot Ulcer Diseases 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000010030 laminating Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QNODIIQQMGDSEF-UHFFFAOYSA-N (1-hydroxycyclohexyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1(O)CCCCC1 QNODIIQQMGDSEF-UHFFFAOYSA-N 0.000 description 1
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 1
- -1 2-hydroxyethoxy Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920006926 PFC Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- MQDJYUACMFCOFT-UHFFFAOYSA-N bis[2-(1-hydroxycyclohexyl)phenyl]methanone Chemical compound C=1C=CC=C(C(=O)C=2C(=CC=CC=2)C2(O)CCCCC2)C=1C1(O)CCCCC1 MQDJYUACMFCOFT-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/04—Acids; Metal salts or ammonium salts thereof
- C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开一种释氧敷料及其制备方法和应用,所述释氧敷料包括依次叠加的载氧水凝胶层、冻干PVA凝胶层和弹性水凝胶层,所述载氧水凝胶层由溶于水中的纳米锂藻土、单体、交联剂、引发剂、乳化剂和全氟化碳光固化而成,所述冻干PVA凝胶层主要由PVA及其复合物质形成多孔冻干凝胶,多孔冻干凝胶包裹过氧化物;所述弹性水凝胶层由溶于水中的纳米锂藻土、单体、交联剂和引发剂光固化而成。应用时,在所述弹性水凝胶层的外表面贴附一层低透气薄膜,所述低透气薄膜延伸并包住所述载氧水凝胶层、所述冻干PVA凝胶层和所述弹性水凝胶层的边缘,从而在所述载氧水凝胶层一侧形成持续稳定的氧气输送,避免氧气爆释和副产物带来毒性。
Description
技术领域
本发明涉及医疗用品技术领域,尤其涉及一种释氧敷料及其制备方法和应用。
背景技术
氧气是伤口愈合和组织再生的一个关键因素,包括炎症、增殖、胶原蛋白合成和血管生成。特别是,充分的氧气供应或高于正常的氧分压已被证明可以促进伤口愈合和组织再生过程。富氧条件可提高细胞内的氧水平,并增加细胞内的活性氧和活性氮水平,从而促进伤口愈合过程,足够的氧分压在伤口愈合的所有阶段中起着重要作用。而缺氧可导致细胞凋亡、组织坏死、延迟愈合和细菌感染。许多慢性伤口如糖尿病足溃疡,都有缺氧区域,这极大地延迟了伤口的愈合过程。
多种氧气治疗方法已被提出并应用于慢性伤口治疗,这些治疗方法可以分为两类:高压氧疗和局部氧疗。高压氧疗需要专用设备(高压氧舱和较大的氧气源),它可导致气胸、高氧诱导的毒性等。局部氧疗采用直接在伤口缺氧部分释放氧气的方式,能降低高压氧毒性风险、增加便携性和降低成本。局部氧疗要想取得较好的疗效,需要向伤口持续的释放纯氧或者高浓度氧,能在创面形成高氧的微环境并能提高创面的氧分压,因而供氧方式对局部氧疗的疗效有重要影响。
现有技术中,为促进足溃疡的愈合,实用新型专利200520069038.0公开一种吹氧靴,可以向发生溃疡等的下肢部位输送氧气的靴子,但是需要依靠外部氧气瓶作为氧气源。也有研究人员利用激光将硅酮基橡胶制成鞋垫,然后制造出储层,可在足部溃疡处释放氧气(MRS Communications,2018,8(3):1-7)。但是该鞋垫需要通过注射泵充满纯氧并储存,通过压力释放氧气,然而氧气持续时间也十分有限。
目前,利用释氧敷料将氧输送到创面上是局部氧疗最有效的方式之一。如一篇公开号为CN 111905142 A的中国发明专利申请公开一种氧气释放水凝胶敷料,其特征在于,包括第一敷料和第二敷料,所述第一敷料由水凝胶敷料、葡萄糖、氧气释放催化剂和具有孔洞结构的聚酯网片制备而成,所述第二敷料包含水凝胶敷料和葡萄糖氧化酶,所述第一敷料和所述第二敷料配合使用。该发明提供的氧气释放水凝胶材料是较为安全的释氧方式,具有良好的透水汽性能和水吸收性能,最终产品在接触空气后能够释放出氧气、碘单质和水。但氧气释放量和释放持续时间仍不太理想,且酶催化体系的储存稳定性有限。
过氧化物是一类最常见的氧源物质,过氧化物包括过氧化氢、过氧化钙、过氧化镁、过碳酸钠等。利用过氧化物的水解或者催化还原生成氧气时,过氧化物首先解离出过氧化氢,进一步分解成水和氧气。这类释氧材料不足之处是:1)过氧化物不易形成均一相,均匀包埋难度较大;2)遇水反应,水性载体体系不稳定;3)形成中间产物过氧化氢(H2O2)和一些副产物如Ca(OH)2等,过氧化氢不仅产生氧气,还产生羟基自由基,这会导致细胞损伤;4)释氧不平稳,释放量前期大,后期明显减小,难以持续稳定的释放氧气。
发明内容
针对现有技术中存在的问题,本发明的目的在于提供一种基于过氧化物且能够持续稳定生成和可控释氧、并避免氧气爆释和副产物带来毒性的释氧敷料。
本发明还提供一种释氧敷料的制备方法和应用。
为达到以上目的,本发明采用如下技术方案。
一种释氧敷料的制备方法,其特征在于,包括以下结构和制备步骤:1)制备载氧水凝胶层,将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂、乳化剂、全氟化碳形成溶液,最后进行光固化反应,制备高拉伸的载氧水凝胶层;2)弹性水凝胶层的制备,将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂形成溶液,最后对溶液进行光固化反应,制备高拉伸的弹性水凝胶层;3)冻干PVA凝胶层的制备,将PVA和复合物质加入DMSO/水混合溶液中,然后加热成溶液,冷却后在加入过氧化物,搅拌分散得到悬浮液;悬浮液经过冷冻—解冻循环处理形成多孔结构后,制备冷冻干燥的多孔片状体;应用时,将载氧水凝胶层、冻干PVA凝胶层、弹性水凝胶层和薄膜层依次叠加在一起组合制成释氧敷料。
更为优选的是,在步骤1)和步骤2)中,所述纳米锂藻土的添加量均为0.5~5wt%。
更为优选的是,在步骤1)和步骤2)中,所述单体为丙烯酰胺、丙烯酸盐、明胶甲基丙烯酰基中的一种或几种,所述单体的添加量均为1~35wt%。
更为优选的是,在步骤1)和步骤2)中,所述交联剂为N,N-亚甲基二丙烯酰胺、双丙烯酸酯类中的一种或几种,所述交联剂的添加量均为0.01-0.5wt%。
更为优选的是,在步骤1)和步骤2)中,所述引发剂为光引发剂,所述引发剂的添加量均为0.01-0.5wt%。
更为优选的是,在步骤1)和步骤2)中,所述乳化剂为泊洛沙姆或者脂质体,所述乳化剂的添加量均为1-15wt%。
更为优选的是,所述全氟化碳为全氟辛烷、全氟萘烷中的一种或几种,所述全氟化碳与所述乳化剂复合形成氧气载体,让氧气增溶;所述全氟化碳的添加量为5-25wt%。
更为优选的是,所述冻干PVA凝胶层中,主体材料为PVA,PVA的含量为1-20wt%;所述复合物质为水溶性胶体或者加热能溶解的亲水聚合物,包括明胶、琼脂或卡拉胶,具有悬浮分散作用,含量为0.1-2wt%;所述过氧化物包括过氧化钙、过氧化镁、过碳酸钠,所述过氧化物的含量为0.1-15wt%。
一种释氧敷料,其特征在于,包括依次叠加的载氧水凝胶层、冻干PVA凝胶层和弹性水凝胶层,所述载氧水凝胶层由溶于水中的纳米锂藻土、单体、交联剂、引发剂、乳化剂和全氟化碳光固化而成,所述冻干PVA凝胶层主要由PVA及其复合物质形成多孔冻干凝胶,多孔冻干凝胶包裹过氧化物;所述弹性水凝胶层由溶于水中的纳米锂藻土、单体、交联剂和引发剂光固化而成。
如上所述的一种释氧凝胶材料在伤口治疗上的应用,应用时,在所述弹性水凝胶层的外表面贴附一层低透气薄膜,所述低透气薄膜延伸并包住所述载氧水凝胶层、所述冻干PVA凝胶层和所述弹性水凝胶层的边缘,从而在所述载氧水凝胶层一侧形成持续稳定的氧气输送。
本发明的有益效果是:工作时,载氧水凝胶层与伤口接触,隔离了冻干PVA凝胶层中过氧化物和副产物和伤口的直接接触,当水凝胶层(载氧层和弹性层)和冻干PVA凝胶层接触时,冻干PVA凝胶层中的过氧化物与水接触,过氧化物发生水解释放出氧气。过氧化物分解释放的氧气一部分进入载氧水凝胶层,载氧水凝胶层中的乳化PFC与氧气作用,吸附大量的氧气使其溶解在水凝胶中,且这类氧气一部分以溶解的状态存在,能较为容易渗透和扩散通过伤口表面的屏障。另外一部分过氧化物分解释放的以气态的形式存在,在皮肤和敷料之间的密封的空间中形成了比通常的大气压略高的氧气压力,是一种高压氧。
本发明中的释氧体系具有多重性能优势,它是一种自身产生氧气的敷料,不需要依靠外部的氧气、装置或者能源驱动,且持续释放氧气时间可达到3天以上,同时避免氧气爆释和副产物带来的毒性。
附图说明
图1所示为本发明提供的释氧敷料的结构示意图。
图2所示为本发明提供的释氧敷料的使用状态示意图。
附图标记说明:1—载氧水凝胶层,2—冻干PVA凝胶层,3—弹性水凝胶层,4—聚氨酯膜层。
具体实施方式
在本发明的描述中,除另有明确规定和限定,如有术语“组装”、“相连”、“连接”术语应作广义去理解,例如,可以是固定连接,也可以是可拆卸连接,或一体地连接;也可以是机械连接;可以是直接相连,也可以是通过中间媒介相连,可以是两个元件内部相连通。对于本领域普通技术人员而言,可以根据具体情况理解上述的术语在本发明中的具体含义。
在发明中,除非另有规定和限定,第一特征在第二特征之“上”或之“下”可以包括第一和第二特征直接接触,也可以包括第一特征和第二特征不是直接接触而是通过它们之间的另外特征接触。而且,第一特征在第二特征“之上”、“之下”和“上面”包括第一特征在第二特征正上方和斜上方,或仅仅是表示第一特征水平高度高于第二特征的高度。第一特征在第二特征 “之上”、“之下”和“下面”包括第一特征在第二特征正下方或斜下方,或仅仅表示第一特征水平高度低于第二特征。
下面结合说明书的附图,对本发明的具体实施方式作进一步的描述,使本发明的技术方案及其有益效果更加清楚、明确。下面通过参考附图描述实施例是示例性的,旨在解释本发明,而不能理解为对本发明的限制。
本发明的附加方面和优点将在下面的描述部分中变得明显,或通过本发明的实践了解到。
如图1所示,一种释氧敷料由多层结构组成,包括:载氧水凝胶层1、封装了过氧化物的冻干PVA凝胶层2、弹性水凝胶层3和聚氨酯膜层4,各层依次叠加,从上到下第1层是载氧水凝胶层,基于水凝胶的接触伤口层,第2层是在聚乙烯醇冷冻凝胶物基体中以过氧化物作为化学氧化物源的生氧层,第3层是弹性水凝胶层,具有极大的缓解压力的能力,第4层是的聚氨酯(或者聚氯乙烯或者硅胶)薄膜层,形成敷料的最外层,具有低气体和蒸汽渗透性。
新型释氧敷料具有多重性能优势:新型释氧敷料可以制备成多种形式,可以制成足垫和贴片敷料;敷料实现持续释放氧气达到5天;产生的氧气一部分以气态氧存在,一部分以溶解的液态氧存在,具有良好的扩散渗透效果;同时实现缓解压力和提供氧气。
载氧水凝胶层通过光固化工艺制备:将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂、乳化剂、全氟化碳形成溶液,最后进行光固化反应,获得高拉伸的水凝胶。本发明的载氧水凝胶层的特点是水凝胶内负载了微米化结构的乳化PFC(全氟化碳),具有良好的氧气增溶作用,能使得水凝胶能负载较多的溶解氧。
弹性水凝胶层也是通过光固化工艺制备:将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂形成溶液,最后对透明溶液进行光固化反应,获得高拉伸的水凝胶。本发明的弹性水凝胶的特点是水凝胶具有高弹性和柔软性,能极大的缓解足底的压力。
冻干PVA凝胶层(产氧层)通过冷冻干燥法制备,首先将含有PVA等的DMSO/水加热到成溶液,冷却后在加入细磨的过氧化物,搅拌分散。这个悬浮液经过冷冻(-20℃,8小时)-解冻(0℃,5小时)循环3次,经过冷冻干燥成多孔片状体,在常温下干燥器中存贮。本发明中的冻干PVA凝胶层能均匀的分散过氧化物,且制备的过程采用低温,冻干后无水存在,使得过氧化物可以长期储存。
释氧敷料在使用前,才将载氧水凝胶层1、冻干PVA凝胶层2和弹性水凝胶层3和聚氨酯膜层4组装在一起形成敷料和足垫,载氧水凝胶层1在压力作用下进入冻干PVA凝胶层2,冻干PVA凝胶层2中的过氧化物与水接触,发生水解作用,过氧化物分解释放出氧气。过氧化物分解释放的氧气一部分进入载氧水凝胶层,载氧水凝胶层中的乳化PFC与氧气作用,吸附大量的氧气使其溶解在水凝胶中,载氧水凝胶层因此负载了比弹性水凝胶层多的多的氧气,且这类氧气以溶解态存在,比气态氧更容易渗透和扩散通过伤口表面的屏障。另外一部分过氧化物分解释放的氧气以气态形式存在,在皮肤和敷料之间的密封空间中形成了比大气压略高的氧气压力,是一种高压氧。
本发明中载氧水凝胶层1和弹性水凝胶层3均为力学增韧的水凝胶,具有较强的力学性能,能耐受较高的压力不会碎裂。水凝胶光固化成片状,可以剪切成任意形状。载氧水凝胶层含有乳化剂和PFC,弹性水凝胶层不含乳化剂和PFC。
本发明中,采用纳米锂藻土作为增强剂,含量为0.5~5wt%。
所采用的单体为常见的商业化单体如丙烯酰胺、丙烯酸盐、明胶甲基丙烯酰基(GelMA)等,含量为1~35wt%。
交联剂为N,N-亚甲基二丙烯酰胺、双丙烯酸酯类中的一种或几种,含量为0.01-0.5wt%。
所述引发剂为通常光引发剂如光引发剂2959(2-羟基-2-甲基-1-[4-(2-羟基乙氧基)苯基]-1-丙酮),光引发剂184( 1-羟环己基苯酮 )等,含量为0.01-0.5wt%。
所采用的乳化剂为泊洛沙姆(Poloxamer)或者脂质体,含量为1-15wt%。
全氟化碳主要包括全氟辛烷、全氟萘烷等,全氟化碳与乳化剂复合形成氧气载体,让氧气增溶形成具有较高浓度氧。其含量为5-25wt%。
冻干PVA凝胶层,主要由PVA及其复合物质形成的多孔冻干凝胶,凝胶包裹过氧化物。水凝胶冻干后成片层状,可以剪切成任意形状。
本发明中,冻干PVA凝胶层中主体材料为PVA,含量为1-20wt%。
所述复合物质为水溶性胶体或者加热能溶解的亲水聚合物,包括明胶、琼脂、卡拉胶等,具有悬浮分散作用,含量为0.1-2wt%。
过氧化物包括过氧化钙、过氧化镁、过碳酸钠等,含量为0.1-15wt%。
聚氨酯膜等是一种商业产品,将该薄膜放置在弹性水凝胶的外部,基于聚氨酯膜等的薄膜层延伸到其他三层的边缘之外,以提供气体和蒸汽不渗透的覆盖层;薄膜的边缘部分涂布压敏胶,可以敷贴在皮肤和足底;敷料的外层尺寸形状可以裁剪。
具体实施过程如下。
水凝胶通过光固化工艺制备,其中载氧水凝胶层中的水凝胶含有乳化剂和PFC,弹性水凝胶层中的水凝胶不含乳化剂和PFC。
实施例1。
一种释氧敷料的制备方法,其特征在于,包括以下步骤。
1)称取0.5克纳米锂藻土溶于98.48克去离子水中,搅拌形成透明溶液,然后依次加入1g单体丙烯酰胺、0.01g化学交联剂N,N-亚甲基二丙烯酰胺、0.01克2959光引发剂,搅拌形成透明溶液,此反应溶液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得弹性水凝胶层A。
2)称取0.5克纳米锂藻土溶于92.48克去离子水中,搅拌形成透明溶液,然后依次加入1g单体丙烯酰胺、0.01g化学交联剂N,N-亚甲基二丙烯酰胺、0.01克2959光引发剂、1g乳化剂和5g全氟辛烷,在匀质器中高速搅拌形成乳液,此反应乳液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得载氧水凝胶层A。
3)将含有1gPVA和0.1g明胶加入98.8gDMSO/水混合溶液中,加热到95℃成溶液,冷却后在加入细磨的0.1g过氧化钙,搅拌分散。这个悬浮液经过冷冻(-20℃,8小时)-解冻(0℃,5小时)循环3次,经过冷冻干燥成多孔片状体,在常温下干燥器中存贮,获得冻干PVA凝胶层A。
4)将弹性水凝胶层A、冻干PVA凝胶层A和载氧水凝胶层A依次叠合在一起,然后用低透气薄膜覆盖弹性水凝胶A的外表面并延伸包住其他三层的边缘制得释氧敷料A。
实施例2。
一种释氧敷料的制备方法,其特征在于,包括以下步骤。
1)称取5克纳米锂藻土溶于59克去离子水中,搅拌形成透明溶液,然后依次加入35g单体丙烯酸盐、0.5g化学交联剂双丙烯酸酯类、0.5克184光引发剂,搅拌形成透明溶液,此反应溶液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得弹性水凝胶层B。
2)称取5克纳米锂藻土溶于19克去离子水中,搅拌形成透明溶液,然后依次加入35g单体丙烯酸盐、0.5g化学交联剂双丙烯酸酯类、0.5克184光引发剂、15g乳化剂和25g全氟辛烷,在匀质器中高速搅拌形成乳液,此反应乳液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得载氧水凝胶层B。
3)将含有20gPVA和2g琼脂加入63gDMSO/水混合溶液中,加热到95℃成溶液,冷却后在加入细磨的15g过氧化镁,搅拌分散。这个悬浮液经过冷冻(-20℃,8小时)-解冻(0℃,5小时)循环3次,经过冷冻干燥成多孔片状体,在常温下干燥器中存贮,获得冻干PVA凝胶层B。
4)将弹性水凝胶层B、冻干PVA凝胶层B和载氧水凝胶层B依次叠合在一起,然后用低透气薄膜覆盖弹性水凝胶B的外表面并延伸包住其他三层的边缘制得释氧敷料B。
实施例3。
一种释氧敷料的制备方法,其特征在于,包括以下步骤。
1)称取3克纳米锂藻土溶于78.8克去离子水中,搅拌形成透明溶液,然后依次加入18g单体明胶甲基丙烯酰基、0.2克2959光引发剂,搅拌形成透明溶液,此反应溶液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得弹性水凝胶层C。
2)称取3克纳米锂藻土溶于68.8克去离子水中,搅拌形成透明溶液,然后依次加入18g单体明胶甲基丙烯酰基、0.2克2959光引发剂、8g乳化剂和10g全氟辛烷,在匀质器中高速搅拌形成乳液,此反应乳液至于模具中,在UV-LED光固化机中在35nm的波长下进行光固化反应,十分钟后取出玻璃器皿,获得载氧水凝胶层C。
3)将含有10gPVA和1g卡拉胶加入81gDMSO/水混合溶液中,加热到95℃成溶液,冷却后在加入细磨的8g过碳酸钠,搅拌分散。这个悬浮液经过冷冻(-20℃,8小时)-解冻(0℃,5小时)循环3次,经过冷冻干燥成多孔片状体,在常温下干燥器中存贮,获得冻干PVA凝胶层C。
4)将弹性水凝胶层C、冻干PVA凝胶层C和载氧水凝胶层C依次叠合在一起,然后用低透气薄膜覆盖弹性水凝胶C的外表面并延伸包住其他三层的边缘制得释氧敷料C。
性能测试。
表1.性能测试结果。
从表1可以看出,本发明制备的释氧敷料具有持续稳定的释氧能力,同时具有优异的抗压能力和弹性,可以同时实现缓解创面处压力和提供氧气的特征。本发明制备的释氧敷料具有高弹性,能较好的缓减足底压力,用户可以穿戴本产品自由行走,氧气可以促进足底溃疡的愈合,凝胶足垫可以极大的缓解足底的压力,减轻病人创面处的痛苦。该释氧敷料既能体现治疗效果,又能兼具护理功能,是多功能集成的敷料。
氧气浓度采用氧气传感器进行测试分析。过氧化物水解后作用后,凝胶层中由大量气泡存在(见图2),证明了气态氧气的存在。载氧水凝胶层中的浓度远大于弹性水凝胶中的浓度,说明载氧水凝胶层中有较多的溶解氧存在。
通过上述的结构和原理的描述,所属技术领域的技术人员应当理解,本发明不局限于上述的具体实施方式,在本发明基础上采用本领域公知技术的改进和替代均落在本发明的保护范围,本发明的保护范围应由各权利要求项及其等同物限定之。具体实施方式中未阐述的部分均为现有技术或公知常识。
英文缩写解释。
PFC,中文名称为全氟化碳。
PVA ,Polyvinyl alcohol的缩写,中文名称为聚乙烯醇。
DMSO,Dimethyl sulfoxide的缩写,中文名称为二甲基亚砜。
Claims (10)
1.一种释氧敷料,其特征在于,包括以下结构和制备步骤:
1)载氧水凝胶层,将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂、乳化剂、全氟化碳形成溶液,最后进行光固化反应,制备高拉伸的载氧水凝胶层;
2)弹性水凝胶层,将纳米锂藻土先溶于水中,然后依次加入单体、交联剂和引发剂形成溶液,最后对溶液进行光固化反应,制备高拉伸的弹性水凝胶层;
3)冻干PVA凝胶层,将PVA和复合物质加入DMSO/水混合溶液中,然后加热成溶液,冷却后在加入过氧化物,搅拌分散得到悬浮液;悬浮液经过冷冻—解冻循环处理形成多孔结构后,制备冷冻干燥的成多孔片状体;
应用时,将载氧水凝胶层、冻干PVA凝胶层、弹性水凝胶层和薄膜层依次叠加在一起组合制成释氧敷料。
2.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,在步骤1)和步骤2)中,所述纳米锂藻土的添加量均为0.5~5wt%。
3.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,在步骤1)和步骤2)中,所述单体为丙烯酰胺、丙烯酸盐、明胶甲基丙烯酰基中的一种或几种,所述单体的添加量均为1~35wt%。
4.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,在步骤1)和步骤2)中,所述交联剂为N,N-亚甲基二丙烯酰胺、双丙烯酸酯类中的一种或几种,所述交联剂的添加量均为0.01-0.5wt%。
5.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,在步骤1)和步骤2)中,所述引发剂为光引发剂,所述引发剂的添加量均为0.01-0.5wt%。
6.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,在步骤1)和步骤2)中,所述乳化剂为泊洛沙姆或者脂质体,所述乳化剂的添加量均为1-15wt%。
7.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,所述全氟化碳为全氟辛烷、全氟萘烷中的一种或几种,所述全氟化碳与所述乳化剂复合形成氧气载体,让氧气增溶;所述全氟化碳的添加量为5-25wt%。
8.根据权利要求1所述的一种释氧敷料的制备方法,其特征在于,所述冻干PVA凝胶层中,主体材料为PVA,PVA的含量为1-20wt%;
所述复合物质为水溶性胶体或者加热能溶解的亲水聚合物,包括明胶、琼脂或卡拉胶,具有悬浮分散作用,含量为0.1-2wt%;
所述过氧化物为过氧化钙、过氧化镁或过碳酸钠,所述过氧化物的含量为0.1-15wt%。
9.一种释氧凝胶敷料,其特征在于,包括依次叠加的载氧水凝胶层、冻干PVA凝胶层和弹性水凝胶层,所述载氧水凝胶层由溶于水中的纳米锂藻土、单体、交联剂、引发剂、乳化剂和全氟化碳光固化而成,所述冻干PVA凝胶层主要由PVA及其复合物质形成多孔冻干凝胶,多孔冻干凝胶包裹过氧化物;所述弹性水凝胶层由溶于水中的纳米锂藻土、单体、交联剂和引发剂光固化而成。
10.如权利要求9所述的一种释氧凝胶敷料在伤口治疗上的应用,应用时,在所述弹性水凝胶层的外表面贴附一层低透气薄膜,所述低透气薄膜延伸并包住所述载氧水凝胶层、所述冻干PVA凝胶层和所述弹性水凝胶层的边缘,从而在所述载氧水凝胶层一侧形成持续稳定的氧气输送。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111008145.2A CN113797380B (zh) | 2021-08-30 | 2021-08-30 | 一种释氧敷料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111008145.2A CN113797380B (zh) | 2021-08-30 | 2021-08-30 | 一种释氧敷料及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113797380A true CN113797380A (zh) | 2021-12-17 |
CN113797380B CN113797380B (zh) | 2023-04-07 |
Family
ID=78941973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111008145.2A Active CN113797380B (zh) | 2021-08-30 | 2021-08-30 | 一种释氧敷料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113797380B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180161476A1 (en) * | 2015-06-30 | 2018-06-14 | Kimberly-Clark Worldwide, Inc. | Hydrogel foam patch for oxygen delivery and method of manufacture |
CN109847089A (zh) * | 2019-01-30 | 2019-06-07 | 郑岩 | 一种高分子材料为载体多种膜构成的伤口供氧敷料 |
CN111116942A (zh) * | 2019-12-30 | 2020-05-08 | 广东省医疗器械研究所 | 一种可控自交联释氧水凝胶组合物及其应用 |
CN112972757A (zh) * | 2021-03-05 | 2021-06-18 | 江苏菌均君隽生物科技有限公司 | 一种全氟萘烷水凝胶促愈合敷料及其制备方法和用途 |
CN113004459A (zh) * | 2021-03-16 | 2021-06-22 | 佛山职业技术学院 | 一种高透明、高拉伸、高导电离子水凝胶的制备方法 |
CN113248736A (zh) * | 2021-05-31 | 2021-08-13 | 华中科技大学 | 一种抗黏连水凝胶及制备方法与制备表皮创伤敷料的应用 |
-
2021
- 2021-08-30 CN CN202111008145.2A patent/CN113797380B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180161476A1 (en) * | 2015-06-30 | 2018-06-14 | Kimberly-Clark Worldwide, Inc. | Hydrogel foam patch for oxygen delivery and method of manufacture |
CN109847089A (zh) * | 2019-01-30 | 2019-06-07 | 郑岩 | 一种高分子材料为载体多种膜构成的伤口供氧敷料 |
CN111116942A (zh) * | 2019-12-30 | 2020-05-08 | 广东省医疗器械研究所 | 一种可控自交联释氧水凝胶组合物及其应用 |
CN112972757A (zh) * | 2021-03-05 | 2021-06-18 | 江苏菌均君隽生物科技有限公司 | 一种全氟萘烷水凝胶促愈合敷料及其制备方法和用途 |
CN113004459A (zh) * | 2021-03-16 | 2021-06-22 | 佛山职业技术学院 | 一种高透明、高拉伸、高导电离子水凝胶的制备方法 |
CN113248736A (zh) * | 2021-05-31 | 2021-08-13 | 华中科技大学 | 一种抗黏连水凝胶及制备方法与制备表皮创伤敷料的应用 |
Non-Patent Citations (1)
Title |
---|
QUNFENG LIU ET AL.: "One-step preparation of a highly transparent, stretchable and conductive ionic nanocomposite hydrogel", 《CHEMICAL PHYSICS LETTERS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113797380B (zh) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090074880A1 (en) | Method for oxygen treatment of intact skin | |
US5792090A (en) | Oxygen generating wound dressing | |
US9572757B2 (en) | Method for oxygen treatment of intact skin | |
Wattel et al. | Hyperbaric oxygen therapy in chronic vascular wound management | |
US20170258826A1 (en) | Methods and Compositions for Improved Delivery Devices | |
EP1631328B1 (en) | Skin dressings containing oxidoreductase enzyme | |
WO2005072783A1 (en) | Improvements in or relating to skin dressings | |
EP2313118B1 (en) | Compositions for use as or in wound dressings | |
WO2007070110A2 (en) | Oxygen producing device for woundcare | |
GB2024012A (en) | Oxygen-generating surgical dressing | |
US8734325B2 (en) | Oxygen therapy with ultrasound | |
CN109069810A (zh) | 用于将治疗气体保存和递送到伤口的系统和方法 | |
CN113456877B (zh) | 有机硅泡沫医用敷料及其制备方法与应用 | |
AU2002357165B9 (en) | Oxygen producing device for woundcare | |
CN113797380B (zh) | 一种释氧敷料及其制备方法和应用 | |
GB2508237A (en) | An ozone releasing wound dressing | |
US10561763B2 (en) | Oxygen generating biomaterial | |
CN112263777B (zh) | 一种氢分子缓释复合敷料及其制备方法 | |
WO2001005445A2 (en) | A carbon dioxide generating device for medical treatment | |
CN112545756A (zh) | 一种医用臭氧油-硅酮泡沫敷贴的制备方法 | |
CN101626805A (zh) | 利用超声波的氧疗 | |
TWM477875U (zh) | 改善糖尿病傷口癒合及降低發炎指數的機能性結構物 | |
TW200817057A (en) | Oxygen producing device for woundcare | |
Coget | Hyperbaric Oxygen Therapy in |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |